Optimal buffer choice of the radiosynthesis of 68Ga-Dotatoc for clinical application

Nuclear Medicine Communications

Volumn 31, Issue 8, 2010, Pages 753-758

  Bauwens, Matthias ^a   Chekol, Rufael ^a   Vanbilloen, Hubert ^a   Bormans, Guy ^a   Verbruggen, Alfons ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

68Ga Dotatoc; automation; buffer; human use

Indexed keywords

BUFFER; EDOTREOTIDE GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; GA(III)-DOTATOC; OCTREOTIDE; ORGANOMETALLIC COMPOUND;

ARTICLE; AUTOMATION; DRUG SYNTHESIS; HUMAN; ISOTOPE LABELING; PH; PROCESS OPTIMIZATION; RADIATION EXPOSURE; RADIOCHEMISTRY; REACTION TIME; TEMPERATURE DEPENDENCE; ANALOGS AND DERIVATIVES; DIAGNOSTIC USE; OCCUPATIONAL EXPOSURE; PREVENTION AND CONTROL; PROCEDURES; SYNTHESIS; TEMPERATURE; TIME;

AUTOMATION; BUFFERS; HUMANS; OCCUPATIONAL EXPOSURE; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; TEMPERATURE; TIME FACTORS;

EID: 77954242710     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32833acb99     Document Type: Article

References (20)

1. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34:1617-1626.
2. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003; 5:42-48.
3. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28:1751-1757.
4. 68Ga-labeled peptides in tumor imaging. J Nucl Med 2005; 46:172S-178S.
5. Breeman WAP, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PM, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28:1421-1429.
6. 18F-radiopharmacy. Ernst Schering Res Found Workshop 2007; 62:215-242.
7. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 3:273-284.
8. 68Ga. Eur J Nucl Med Mol Imaging 2005; 32:478-485.
9. 68Ga-DOTA-D-Phe1-Tyr3- Octreotide kinetics in patients with meningiomas. J Nucl Med 2005; 46:763-769.
10. 68Ga for medical application. J Nucl Med 2007; 48:1741-1748.
11. Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, et al. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 2002; 29:147-157.
12. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004; 31:1097-1104.
13. 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem 2004; 15:554-560.
14. Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, Hennig M. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem-Eur J 1999; 5:1974-1981.
15. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006; 33:1115-1122.
16. 68Ga-labeled peptide. Nucl Med Biol 2008; 35:529-536.
17. Weiner RE, Thakur ML. Chemistry of gallium and indium radiopharmaceuticals. In: Welch MJ, Redvanly CS, editors. Handbook of radiopharmaceuticals: radiochemistry and applications. New York: John Wiley & Sons; 2003. pp. 363-399.
18. Heppeler A, André JP, Buschmann I, Wang X, Reubi JC, Hennig M, et al. Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting. Chem-Eur J 2008; 14:3026-3034.
19. IUPAC Technical Report. Critical evaluation of stability constants of metal complexes of complexones for biomedical and environmental applications. Pure Appl Chem 2005; 77:11445-11495.
20. Liu S, Edwards DS, Harris AR, Ziegler MC, Poirier MJ, Ewels BA, et al. Towards developing a non-SnCl2 formulation for RP444, a new radiopharmaceutical for thrombus imaging. J Pharm Sci 2001; 90:114-123.